Daniel A Arber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3430088/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|
| 1 | The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127, 2391-2405. | 1.4 | 7,429 |
| 2 | The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 2009, 114, 937-951. | 1.4 | 3,864 |
| 3 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228. | 1.4 | 814 |
| 4 | Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1116-25. | 7.1 | 307 |
| 5 | Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270. | 0.9 | 210 |
| 6 | Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651. | 1.4 | 192 |
| 7 | Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood, 2009, 113, 1906-1908. | 1.4 | 149 |
| 8 | Bone Marrow Biopsy Involvement by Non-Hodgkin's Lymphoma. American Journal of Surgical Pathology, 2005, 29, 1549-1557. | 3.7 | 119 |
| 9 | Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Modern Pathology, 2015, 28, 706-714. | 5.5 | 114 |
| 10 | Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864. | 5.5 | 104 |
| 11 | Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949. | 3.5 | 93 |
| 12 | Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. Archives of Pathology and Laboratory Medicine, 2017, 141, 1342-1393. | 2.5 | 88 |
| 13 | <i>TP53</i> mutation defines a unique subgroup within complex karyotype deÂnovo and therapy-related MDS/AML. Blood Advances, 2022, 6, 2847-2853. | 5.2 | 87 |
| 14 | Mixed Phenotype Acute Leukemia. American Journal of Clinical Pathology, 2014, 142, 803-808. | 0.7 | 62 |
| 15 | Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360. | 3.5 | 62 |
| 16 | Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 r chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222. | gBT /Overlo 5.5 | ock 10 Tf 50 2 52 |
| 17 | Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498. | 5.5 | 50 |
| 18 | The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. | 3.4 | 48 |

Seminars in Hematology, 2019, 56, 90-95.

DANIEL A ARBER

| # | Article | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Modern Pathology, 2016, 29, 1212-1220. | 5.5 | 46 |
| 20 | Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Modern Pathology, 2017, 30, 382-392. | 5.5 | 43 |
| 21 | STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica, 2014, 99, e105-e105. | 3.5 | 37 |
| 22 | Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology, 2018, 31, 690-704. | 5.5 | 35 |
| 23 | Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology American Society of Hematology Education Program, 2015, 2015, 294-298. | 2.5 | 34 |
| 24 | Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. American Journal of Hematology, 2022, 97, 514-518. | 4.1 | 30 |
| 25 | Comparison of therapyâ€related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology, 2020, 95, 799-808. | 4.1 | 26 |
| 26 | Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385. | 5.5 | 25 |
| 27 | Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). American Journal of Clinical Pathology, 2020, 154, 731-741. | 0.7 | 22 |
| 28 | Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2019, 20, 15. | 3.0 | 21 |
| 29 | Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology, 2020, 42, 418-422. | 1.3 | 21 |
| 30 | Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685. | 5.5 | 21 |
| 31 | Acute Myeloid Leukemia With Monosomal Karyotype. American Journal of Clinical Pathology, 2014, 142, 190-195. | 0.7 | 20 |
| 32 | Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis. American Journal of Surgical Pathology, 2018, 42, 885-890. | 3.7 | 19 |
| 33 | Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma. Human Pathology, 2016, 55, 39-43. | 2.0 | 18 |
| 34 | Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American Journal of Clinical Pathology, 2017, 148, 49-57. | 0.7 | 18 |
| 35 | Update on the pathologic diagnosis of chronic myelomonocytic leukemia. Modern Pathology, 2019, 32, 732-740. | 5.5 | 18 |
| 36 | Acute Myeloid Leukemia With Myelodysplasia-Related Changes: A New Definition. Surgical Pathology Clinics, 2010, 3, 1153-1164. | 1.7 | 15 |

DANIEL A ARBER

| # | Article | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 416-422. | 1.2 | 15 |
| 38 | Revisiting erythroleukemia. Current Opinion in Hematology, 2017, 24, 146-151. | 2.5 | 15 |
| 39 | Lymphoid blast transformation in an MPN with <i>BCR-JAK2</i> treated with ruxolitinib: putative mechanisms of resistance. Blood Advances, 2021, 5, 3492-3496. | 5.2 | 14 |
| 40 | Genetic Testing in the Diagnosis and Biology of Acute Leukemia. American Journal of Clinical Pathology, 2019, 152, 322-346. | 0.7 | 13 |
| 41 | Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Modern Pathology, 2016, 29, 996-1003. | 5.5 | 12 |
| 42 | Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Advances, 2020, 4, 4924-4928. | 5.2 | 12 |
| 43 | Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2017, 141, 1101-1106. | 2.5 | 11 |
| 44 | High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 740-748. | 1.2 | 11 |
| 45 | How I investigate chronic myelomonocytic leukemia. International Journal of Laboratory Hematology, 2020, 42, 101-108. | 1.3 | 9 |
| 46 | Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31. | 5.5 | 9 |
| 47 | The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma. Human Pathology, 2015, 46, 629-633. | 2.0 | 8 |
| 48 | Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology, 2021, 34, 1358-1366. | 5.5 | 8 |
| 49 | Challenges in Consolidated Reporting of Hematopoietic Neoplasms. Surgical Pathology Clinics, 2013, 6, 795-806. | 1.7 | 7 |
| 50 | Diagnosis of classic Hodgkin lymphoma on bone marrow biopsy. Histopathology, 2020, 76, 934-941. | 2.9 | 7 |
| 51 | Vascular neoplasms and non-neoplastic vascular lesions of the spleen. Seminars in Diagnostic Pathology, 2021, 38, 154-158. | 1.5 | 6 |
| 52 | Erythroleukemia: an Update. Current Oncology Reports, 2021, 23, 69. | 4.0 | 6 |
| 53 | Primary Gastric Hodgkin's Lymphoma: An Extremely Rare Entity and A Diagnostic Challenge. Digestive Diseases and Sciences, 2015, 60, 2923-2926. | 2.3 | 5 |
| 54 | The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810. | | 5 |

DANIEL A ARBER

| # | Article | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Aggressive Bâ€cell lymphomas with a primary bone marrow presentation. Histopathology, 2020, 77, 369-379. | 2.9 | 4 |
| 56 | How I Diagnose Acute Leukemia of Ambiguous Lineage. American Journal of Clinical Pathology, 2022, 158, 27-34. | 0.7 | 4 |
| 57 | A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Modern Pathology, 2018, 31, 873-880. | 5.5 | 3 |
| 58 | Non-hematopoietic neoplastic and pseudoneoplastic lesions of the spleen. Seminars in Diagnostic Pathology, 2021, 38, 159-164. | 1.5 | 3 |
| 59 | <i>NPM1</i> exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring. EJHaem, 2022, 3, 962-965. | 1.0 | 2 |
| 60 | EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 621-646. | 2.8 | 2 |
| 61 | Challenges and limitations in the primary diagnosis of Tâ€cell and natural killer cell/Tâ€cell lymphoma in bone marrow biopsy. Histopathology, 2020, 77, 2-17. | 2.9 | 1 |
| 62 | Pathology of the spleen: INTRODUCTION. Seminars in Diagnostic Pathology, 2021, 38, 111. | 1.5 | 1 |
| 63 | AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome Blood, 2009, 114, 2638-2638. | 1.4 | 1 |
| 64 | GLUT1 Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues. American Journal of Clinical Pathology, 2022, 158, 228-234. | 0.7 | 1 |
| 65 | Why Is Hematopathology so Complicated?. Surgical Pathology Clinics, 2013, 6, ix. | 1.7 | 0 |
| 66 | Biological characterization of stage I follicular lymphoma according to extranodal or nodal primary origin and t(14;18) status using highâ€resolution arrayâ€based comparative genomic hybridization. American Journal of Hematology, 2015, 90, E151-2. | 4.1 | 0 |
| 67 | Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System Blood, 2008, 112, 922-922. | 1.4 | 0 |
| 68 | 2008 WHO Classification of Pediatric AML Blood, 2010, 116, 1044-1044. | 1.4 | 0 |
| 69 | Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status–Based Treatment Stratification. Blood, 2010, 116, 3313-3313. | 1.4 | 0 |
| 70 | Immature T-Cell Populations in Lymph Nodes of Castleman Disease and Angioimmunoblastic T-Cell Lymphoma Suggest Alternate Sites of T-Cell Development,. Blood, 2011, 118, 3238-3238. | 1.4 | 0 |
| 71 | Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847. | 1.4 | 0 |
| | | | |

72 Myelodysplastic/Myeloproliferative Neoplasms. , 2020, , 162-180.